心可舒片对非ST段抬高型急性冠状动脉综合征PCI患者非靶病变粥样硬化斑块的影响

目的 观察心可舒片联合西药对非ST段抬高型急性冠状动脉综合征经皮冠状动脉介入治疗（percutaneous coronary intervention，PCI）患者非靶病变粥样硬化斑块的影响。方法 将60例非ST段抬高型急性冠脉综合征PCI患者，采用随机数字表法随机分为对照组和治疗组，每组30例；对照组予以常规西药，治疗组在此基础上联合心可舒片；观察两组患者治疗前后血脂水平、炎症因子水平以及非靶病变血管粥样硬化斑块的血管内超声（intravascular ultrasound，IVUS）影像学指标。结果 治疗后两组患者总胆固醇、三酰甘油、低密度脂蛋白胆固醇、超敏C反应蛋白、白细胞介素-6水平、斑块负荷均显著降低（P＜0.05），高密度脂蛋白胆固醇水平、最小管腔面积均显著上升（P＜0.05），且治疗组上述指标改善程度较对照组更优（P＜0.05）。结论 心可舒片能显著改善患者血脂、炎症因子水平以及非靶病变血管粥样硬化斑块IVUS影像学指标。

Effect of Xinkeshu Tablet on Non-target Atherosclerotic Plaques in Patients Undergoing Percutaneous Coronary Intervention for Non-ST-segment Elevation Acute Coronary Syndrome

Objective To investigate the effect of Xinkeshu Tablet combined with Western medicine therapy on non-target plaques in patients undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome. Methods A total of 60 patients with non-ST-segment elevation acute coronary syndrome were divided into treatment group and control group using a random number table, with 30 patients in each group. The patients in the control group were given conventional Western medicine, and those in the treatment group were given Xinkeshu Tablet in addition to the treatment in the control group. The two groups were observed in terms of blood lipids, inflammatory factors, and intravascular ultrasound(IVUS) indices of non-target atherosclerotic plaques. Results After treatment, both groups had significant reductions in total cholesterol, triglyceride, low-density lipoprotein cholesterol,hyper-sensitive C-reactive protein,interleukin-6, and plaque burden (P<0.05) and significant increases in high-density lipoprotein cholesterol and minimum lumen area (P<0.05), and the treatment group had significantly better improvements than the control group (P<0.05). Conclusion Xinkeshu Tablet can significantly improve blood lipids, inflammatory factors, and IVUS indices of non-target atherosclerotic plaques.